Preventive treatment of migraine

Reviews in Neurological Diseases

Volumn 2, Issue 4, 2005, Pages 167-175

  Silberstein, Steven D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anticonvulsants; Antidepressants; Beta blockers; Migraine; Prevention; Prophylaxis

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOXEPIN; FENOPROFEN; GABAPENTIN; LISINOPRIL; METOPROLOL; NADOLOL; NEUROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PIZOTIFEN; PROPRANOLOL; PROTRIPTYLINE; SEROTONIN ANTAGONIST; SERTRALINE; TERTIARY AMINE; TIMOLOL; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ABDOMINAL PAIN; ALOPECIA; ANHIDROSIS; ANOREXIA; ANXIETY DISORDER; BLURRED VISION; BRADYCARDIA; CLOSED ANGLE GLAUCOMA; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; EDEMA; EPIGASTRIC DISCOMFORT; FAMILIAL HEMIPLEGIC MIGRAINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEPATITIS; HUMAN; HYPERANDROGENISM; HYPESTHESIA; HYPOTENSION; IMPOTENCE; INSOMNIA; LANGUAGE DISABILITY; LETHARGY; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; MUSCLE DISEASE; MYOPIA; NAUSEA; NIGHTMARE; OBESITY; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PROPHYLAXIS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TACHYCARDIA; TASTE DISORDER; TERATOMA; TREMOR; URINE RETENTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; SEROTONIN ANTAGONISTS;

EID: 29744438844     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994;44:4-5.
2. Silberstein SD. Migraine. Lancet. 2004;363:381-391.
3. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology [serial online]. 2000;55:754-762. Available at: http://www.neurology. org. Accessed April 25, 2000.
4. Silberstein SD. Headaches in pregnancy. Neurol Clin. 2004;22:727-756.
5. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
6. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885-894.
7. Tfelt-Hansen P. Prioritizing acute pharmacotherapy of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York, NY: Lippincott Williams & Wilkins; 2000:453-456.
8. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004;24 (suppl 2):2-7.
9. Silberstein SD. Migraine and pregnancy. Neurologic Clinics. 1997;15:209-231.
10. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache. 1986;26:490-493.
11. Ryan RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache. 1983;23:26-31.
12. Ryan RE. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J. 1984;108:1156-1159.
13. Sudilovsky A, Stern MA, Meyer JH. Nadolol: the benefits of an adequate trial duration in the prophylaxis of migraine. Headache. 1986;26:325.
14. Gray RN, Goslin RE, McCrory DC, et al. Drug Treatments for the Prevention of Migraine Headache. Technical review 2.3. Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025. 1999. Available from the National Technical Information Service, Accession No. 127953.
15. Pradalier A, Serratrice G, Colard M, et al. Long-acting propranolol on migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9:247-253.
16. Diamond S, Solomon GD, Freitag FG, Mehta ND. Long-acting propranolol in the prophylaxis of migraine. Headache. 1987;27:70-72.
17. Sudilovsky A, Elkind AH, Ryan RE, et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache. 1987;27:421-426.
18. Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand. 1990;82:34-38.
19. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves post-herpetic neuralgia. Clin Pharmacol Ther. 1990;47:305-312.
20. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc. 1990;65:1227-1236.
21. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York, NY: Pergamon; 1990:383-435.
22. Wauquier A, Ashton D, Marranes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia. 1985;5(suppl 2):119-120.
23. Ophoff RA, Terwindt GM, Vergouwe MN. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4. Cell Tiss Res. 1996;87:543-552.
24. Coulam CB, Annagers JR. New anticonvulsants reduce the efficacy of oral contraception. Epilepsia. 1979;20:519-525.
25. Hansten PD, Horn JR. Drug interaction. Newsletter 1985;5:7-10. Available at: www. med.unc.edu/medicine/edursrc/drug_int.htm.
26. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol: a comparison with placebo. Cephalalgia. 1987;7(suppl 6):457-458.
27. Jensen R, Brinck T, Olesen J. Sodium valproate has prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:241-244.
28. Klapper JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Quarterly. 1995;5:50-53.
29. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
30. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol). S Afr Med J. 1970;44:75-80.
31. Stensrud P, Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. Headache. 1979;19:333-334.
32. Mathew NT. Gabapentin in migraine prophylaxis. Cephalalgia. 1996;16(abstract 29):367.
33. Wessely P, Baumgartner C, Klinger D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia. 1987;7(suppl 6):477-478.
34. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-128.
35. Behan PO. Prophylactic treatment for migraine: a comparison of pizotifen and clonidine. Cephalalgia. 1985;5(suppl 3):524-525.
36. Klapper JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103-108.
37. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
38. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology. 1994;44:647-651.
39. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. For the Depakote ER Migraine Study Group. Neurology. 2003;58:1652-1659.
40. Silberstein SD. Divalproex sodium in headache-literature review and clinical guidelines. Headache. 1996;36:547-555.
41. Vainionpaa LK, Rattya J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol. 1999;45:444-450.
42. Freitag FG, Diamond S, Diamond M, Urban G. Divalproex in the long-term treatment of chronic daily headache. Headache. 2001;41:271-278.
43. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia. 1994;35:450-460.
44. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: a pilot study. [abstract]. Cephalalgia. 1999;19:379-380.
45. Edwards KR, Glantz MJ, Shea P, et al. A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. [abstract]. Cephalalgia. 2000;20:316.
46. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. [abstract]. Neurology. 2000;54(7 suppl 30):A15.
47. Silberstein SD, Bhattacharaya S, Neto W, Jacobs D. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Cephalagia. In press.
48. Brandes JL, Jacobs D, Neto W, Bhattacharaya S. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled parallel study (MIGR-002). [abstract]. Neurology. 2003;60(suppl 1):A238.
49. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943-950.
50. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium [letter]. Headache. 2002;42:85.
51. Sachedo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia. 1997;38:294-300.
52. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003.
53. Schrader H, Stovner LJ, Heide G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. Br Med J. 2001;322:19-22.
54. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
55. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280:1569-1575.
56. Pittler MH, Ernst E. Feverfew for preventing migraine. The Cochrane Database of Systematic Reviews. 2004;1:CD002286.
57. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240-2244.
58. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50:466-470.
59. Sandor PS, diClemente L, Coppola G, et al. Coenzyme Q10 for migraine prophylaxis: a randomized controlled trial. [abstract]. Cephalalgia. 2003;23:577.
60. Silberstein SD, Lipton RB, Goadsby PJ. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Goadsby PJ, eds. Headache in Clinical Practice. Oxford, England: Isis Medical Media Ltd., 1998:61-90.
61. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia. 1997;17:67-72.
62. Silberstein SD, Lipton RB, Breslau N. Migraine: association with personality characteristics and psychopathology. Cephalalgia. 1995;15:337-369.
63. Mathew NT, Saper JR, Silberstein SD, et al. Prophylaxis of migraine headaches with divalproex sodium. Arch Neurol. 1995;52:281-286.
64. Bowden CL, Brugger AM, Swann AC. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918-924.
65. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23:961-962.